How Can Employers Balance Drug Plan Costs Without Limiting Access to Care?

GLP-1 therapies, generics, therapeutic options: drug plan design has never been more strategic. How can employers balance cost control with employee access to care?

As employers navigate rising drug costs and growing demand for GLP-1 therapies, decisions around generics, manufacturer savings programs and therapeutic alternatives are becoming increasingly important. The challenge is containing costs without compromising employees’ access to the medications they need.

Jarred French, Senior Benefits Consultant at BFL CANADA, shares his perspective in the latest Benefits Canada article.